| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,320,000 |
| Market
Cap: |
7.07(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$80.05 - $147.48 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8.1 |
| Insider 6 Months : 8.1 |
| Insider 3/6 Months : 16.5 |
|
| Guru Rank Number : 1068 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Axsome Therapeutics is a biopharmaceutical company developing therapies for the management of central nervous system (CNS) conditions that have limited treatment options. Co.'s primary CNS portfolio includes: AXS-05, which is an oral, investigational N-methyl-D-aspartate receptor antagonist with multimodal activity under development for the treatment of CNS disorders; AXS-07, which is an oral, multi-mechanistic, investigational medicine under development for the acute treatment of migraine; AXS-12, which is an oral, investigational medicine in development for the treatment of narcolepsy; and AXS-14, which is an oral, investigational medicine in development for the treatment of fibromyalgia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,575 |
1,575 |
1,575 |
1,575 |
| Total Buy Value |
$200,466 |
$200,466 |
$200,466 |
$200,466 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
430,577 |
556,458 |
574,458 |
708,605 |
| Total Sell Value |
$53,507,090 |
$66,936,215 |
$69,210,218 |
$79,777,889 |
| Total People Sold |
4 |
6 |
7 |
7 |
| Total Sell Transactions |
17 |
28 |
31 |
39 |
| End Date |
2025-08-24 |
2025-05-23 |
2024-11-22 |
2023-11-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tabuteau Herriot |
Chief Executive Officer |
• • • |
2025-11-05 |
4 |
AS |
$134.49 |
$2,928,520 |
D/D |
(21,775) |
7,229 |
|
10% |
|
| Tabuteau Herriot |
Chief Executive Officer |
• • • |
2025-11-05 |
4 |
OE |
$8.02 |
$174,636 |
D/D |
21,775 |
29,004 |
|
- |
|
| Tabuteau Herriot |
Chief Executive Officer |
• • • |
2025-11-04 |
4 |
AS |
$133.79 |
$6,750,910 |
D/D |
(50,459) |
7,229 |
|
11% |
|
| Tabuteau Herriot |
Chief Executive Officer |
• • • |
2025-11-04 |
4 |
OE |
$8.02 |
$404,681 |
D/D |
50,459 |
57,688 |
|
- |
|
| Tabuteau Herriot |
Chief Executive Officer |
• • • |
2025-11-03 |
4 |
AS |
$132.34 |
$12,136,240 |
D/D |
(91,705) |
7,229 |
|
10% |
|
| Tabuteau Herriot |
Chief Executive Officer |
• • • |
2025-11-03 |
4 |
OE |
$8.02 |
$735,474 |
D/D |
91,705 |
98,934 |
|
- |
|
| Tabuteau Herriot |
Chief Executive Officer |
• • • |
2025-10-08 |
4 |
AS |
$118.84 |
$1,518,062 |
D/D |
(12,774) |
7,229 |
|
26% |
|
| Tabuteau Herriot |
Chief Executive Officer |
• • • |
2025-10-08 |
4 |
OE |
$8.02 |
$102,447 |
D/D |
12,774 |
20,003 |
|
- |
|
| Tabuteau Herriot |
Chief Executive Officer |
• • • |
2025-10-07 |
4 |
AS |
$118.77 |
$1,590,330 |
D/D |
(13,390) |
7,229 |
|
26% |
|
| Tabuteau Herriot |
Chief Executive Officer |
• • • |
2025-10-07 |
4 |
OE |
$8.02 |
$107,388 |
D/D |
13,390 |
20,619 |
|
- |
|
| Tabuteau Herriot |
Chief Executive Officer |
• • • |
2025-10-06 |
4 |
AS |
$120.17 |
$2,309,667 |
D/D |
(19,220) |
7,229 |
|
25% |
|
| Tabuteau Herriot |
Chief Executive Officer |
• • • |
2025-10-06 |
4 |
OE |
$8.02 |
$154,144 |
D/D |
19,220 |
26,449 |
|
- |
|
| Jacobson Mark L. |
Chief Operating Officer |
• – – |
2025-09-22 |
4 |
AS |
$115.96 |
$1,159,600 |
D/D |
(10,000) |
0 |
|
27% |
|
| Jacobson Mark L. |
Chief Operating Officer |
• – – |
2025-09-22 |
4 |
OE |
$2.85 |
$28,500 |
D/D |
10,000 |
10,000 |
|
- |
|
| Jacobson Mark L. |
Chief Operating Officer |
• – – |
2025-09-16 |
4 |
AS |
$114.23 |
$5,241,127 |
D/D |
(45,783) |
0 |
|
31% |
|
| Jacobson Mark L. |
Chief Operating Officer |
• – – |
2025-09-16 |
4 |
OE |
$4.85 |
$196,500 |
D/D |
40,000 |
40,000 |
|
- |
|
| Tabuteau Herriot |
Chief Executive Officer |
• • • |
2025-09-16 |
4 |
AS |
$114.19 |
$2,251,713 |
D/D |
(19,719) |
7,229 |
|
31% |
|
| Tabuteau Herriot |
Chief Executive Officer |
• • • |
2025-09-16 |
4 |
OE |
$8.02 |
$158,146 |
D/D |
19,719 |
26,948 |
|
- |
|
| Tabuteau Herriot |
Chief Executive Officer |
• • • |
2025-09-15 |
4 |
AS |
$117.37 |
$1,790,362 |
D/D |
(15,254) |
7,229 |
|
28% |
|
| Tabuteau Herriot |
Chief Executive Officer |
• • • |
2025-09-15 |
4 |
OE |
$8.02 |
$122,337 |
D/D |
15,254 |
22,483 |
|
- |
|
| Tabuteau Herriot |
Chief Executive Officer |
• • • |
2025-09-12 |
4 |
AS |
$118.96 |
$3,319,817 |
D/D |
(27,907) |
7,229 |
|
26% |
|
| Tabuteau Herriot |
Chief Executive Officer |
• • • |
2025-09-12 |
4 |
OE |
$8.02 |
$223,814 |
D/D |
27,907 |
35,136 |
|
- |
|
| Coleman Mark |
|
– • – |
2025-09-08 |
4 |
B |
$127.20 |
$200,466 |
D/D |
1,575 |
48,212 |
0.01 |
11% |
|
| Saad Mark E |
|
– • – |
2025-09-05 |
4 |
AS |
$125.07 |
$1,141,514 |
D/D |
(9,127) |
10,002 |
|
19% |
|
| Saad Mark E |
|
– • – |
2025-09-05 |
4 |
OE |
$9.00 |
$82,143 |
D/D |
9,127 |
19,129 |
|
- |
|
103 Records found
|
|
Page 1 of 5 |
|
|
6.13 (4.28%) 
